Acceleron Pharma Inc.

06/11/2021 | Press release | Distributed by Public on 06/11/2021 01:10

Bristol Myers Squibb and Acceleron Present First Results from Phase 2 BEYOND Study of Reblozyl® (luspatercept-aamt) in Adults with Non-Transfusion Dependent (NTD) Beta Thalassemia